Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1719-1725

  Xia, Qing ^a   Zhu, Zhihua ^a   Wang, Jian ^a   Situ, Dongrong ^a   Zhou, Ningning ^a   Jang, Wenqi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

HER2; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84868114884     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0429-9     Document Type: Article

References (31)

1. Carney DN. Lung cancer-time to move on from chemotherapy. N Engl J Med. 2002;346:126-8.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
3. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol. 1995;13:1221-30.
4. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1:5-13.
5. Situ D, Wang J, Shao W, Zhu ZH. Assessment and treatment of cancer pain: from Western to Eastern. Ann Palliat Med. 2012;1:32-44.
6. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001;10:139-52.
7. Schuell B, Gruenberger T, Scheithauer W, et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123.
8. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7:1850-5.
9. Smith HS. Painful boney metastases. Ann Palliat Med. 2012;1:14-31.
10. Mimura K, Kono K, Hanawa M, et al. Frequencies of HER2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:1253-60.
11. Noguchi M, Murakami M, Bennett W, et al. Biological consequences of overexpression of a transfected HER2 gene in immortalized human bronchial epithelial cells. Cancer Res. 1993;53:2035-43.
12. Yu D, Wang SS, Dulski KM, et al. HER2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994;54:3260-6.
13. Cox G, Jones J, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax. 2001;56:561-6.
14. Carbognani P, Tincani G, Crafa P, et al. Biological markers in non-small cell lung cancer. Retrospective study of 10-year follow-up after surgery. J Cardiovasc Surg (Torino). 2002;43:545-8.
15. Kuyama S, Hotta K, Tabata M, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:477-82.
16. Korrapati V, Gaffney M, Larsson LG, et al. Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clin Lung Cancer. 2001;2:216-9.
17. Szelachowska J, Jelen M, Kornafel J. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer. Anticancer Res. 2006;26:3871-6.
18. Selvaggi G, Scagliotti GV, Torri V, et al. HER2/neu overexpression in patients with radically resected non small cell lung carcinoma. Impact on long-term survival. Cancer. 2002;94:2669-74.
19. Tan D, Deeb G, Wang J, et al. HER2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: A study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol. 2003;12:201-11.
20. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 1998;157:1093-7.
21. Toh CK, Ahmad B, Soong R, et al. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. J Thorac Oncol. 2010;5:17-22.
22. Pelosi G, Del Curto B, Dell'Orto P, et al. Lack of prognostic implications of HER2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the Lung. Int J Cancer. 2005;113:101-8.
23. Xu JM, Han Y, Duan HQ, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with Gefitinib. J Cancer Res Clin Oncol. 2009;135:771-82.
24. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-92.
25. Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5:1922-32.
26. Takenaka M, Hanagiri T, Shinohara S, et al. The prognostic significance of her2 overexpression in non-small cell lung cancer. Anticancer Res. 2011;31:4631-6.
27. Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990;50:5184-7.
28. Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (p185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990;50:421-5.
29. Awaya H, Takeshima Y, Furonaka O, et al. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol. 2005;58:1076-80.
30. Ochiai A, Akimoto S, Kanai Y, et al. c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun. 1994;205:73-8.
31. Giatromanolaki A, Koukourakis MI, O'Byrne K, et al. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res. 1999;16:3819-25.